Skip to content

LBRX: Held by 4 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›LB PHARMACEUTICALS INC (LBRX)

LB PHARMACEUTICALS INC

LBRX

Held by 4 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

4 funds opened new positions. Next phase3 readout (LB-102 (50 mg tablet)): Jun 2027. Short interest: 18.1% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: Heather D. TurnerIPO: 2025Website ↗

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.0/10

4 funds opened new positions●●

No recent insider activity●●

Phase3 readout expected Jun 2027●●

Held by 4 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

4 specialist funds hold LBRX with a Phase 3 in 353 days for LB-102 (50 mg tablet) (Schizophrenia)

+2 more upcoming catalysts

Deep Track Capital Commodore Capital Baker Bros. Advisors RA Capital Management

Fund Holdings

4 fund convergence

Deep Track CapitalHeld 3Q

Commodore CapitalHeld 3Q

Baker Bros. AdvisorsHeld 3Q

RA Capital ManagementHeld 3Q ↑

Position history (shares)

Deep Track Capital

3Q

Commodore Capital

3Q

Baker Bros. Advisors

3Q

RA Capital Management

3Q

AI Signal

Signal Note: LBRX

Baker Bros. initiated a $3.2M position in LB Pharmaceuticals, joining three other specialist funds (RA Capital, Commodore, Deep Track) in what appears to be a high-conviction thesis around LB-102, a schizophrenia/bipolar I candidate with near-term Phase 2 (bipolar, Feb 2028) and Phase 3 (schizophrenia, June 2027) readouts.

Unlock full AI analysis — 14-day free trial

3 quarters

Position Trend

Nov 14, 2025

$107.8M

4 funds

Feb 13, 2026

$74.6M

1 fund

Feb 17, 2026

$87.0M

3 funds

May 15, 2026

$179.1M

4 funds

+66% total institutional value over 4 quarters

Short Interest

High short interestSI rising 2 periods (+7.2%)

Short Shares

4.30M

Change

+7.1%

Days to Cover

23.4

% of Float

18.1%

Settlement

Jun 15, 2026

Short interest over 10 periods

Catalysts

Phase 3Q2 2027LB-102 (50 mg tablet)SchizophreniaNCT07363577

Phase 2Q1 2028LB-102Bipolar I DisorderNCT07494305

Phase 3Q4 2028LB-102SchizophreniaNCT07369154

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/ACommodore Capital6.8%May 15, 2026

SC 13G/ARA Capital Management8.7%Feb 17, 2026

SC 13D/ADeep Track Capital9.4%Feb 10, 2026

SC 13DDeep Track Capital12.0%Sep 19, 2025

SC 13GRA Capital Management7.5%Sep 19, 2025

SC 13GCommodore Capital5.5%Sep 18, 2025

Recent News & Research

PubMed

Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial.

# Investment Summary: LB-102 Clinical Trial Results LB Pharmaceuticals' Phase 3 trial demonstrates LB-102 met efficacy and safety endpoints in acute schizophrenia, establishing clinical proof-of-concept for the compound and supporting potential regulatory filing. The trial's publication in a high-impact journal (JAMA Psychiatry) provides third-party validation, which is valuable for clinical credibility and de-risking the program ahead of FDA submission. Commercial significance depends on comparative efficacy, tolerability profile versus existing antipsychotics, and market positioning—key details that would inform competitive differentiation in a crowded space. **Investor note:** Positive Phase 3 data is necessary but not sufficient; monitor for regulatory feedback, manufacturing scale-up readiness, and management guidance on launch timeline and market penetration strategy.

Jul 1, 2026

Position Details

Deep Track CapitalHELDMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

11 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

ARGX1 fund ACAD1 fund RVMD1 fund VTVT1 fund REPL1 fund KYMR1 fund MDGL1 fund DBVTF1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: